Red blood cell therapy for advanced cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new treatment that attaches an immune-boosting drug to your red blood cells. It is for people with advanced solid tumors who have not responded to standard treatments or cannot take them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed advanced solid tumor that cannot be removed by surgery.
- You must have tried standard treatments without success, or no standard treatment exists for you.
- You need to be up and about most of the day (ECOG score 0 or 1).
- You must not have serious heart, lung, bleeding, or other medical conditions.
- You must not have cancer that has spread to the brain causing symptoms needing steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early trial studies whether an engineered (lab-made) red blood cell treatment is safe and tolerable, and whether it may show early anti-cancer activity. It may help people with advanced cancers whose disease has not responded well to standard options.
This study tests a new immunotherapy using specially engineered immune cells (called TCR-enhanced Vδ2 T cells) to treat blood cancers or solid tumors that haven't responded to standard treatments. The goal is to see if these cells can safely shrink tumors and improve survival.
This trial tests a personalized cell therapy (CAR-NK) using donor immune cells that are engineered to find and attack one or two markers on advanced solid tumors. It may be an option for people whose tumors have these specific markers and have exhausted other treatments.
This study tests a new type of cell therapy called anti-HER2-CAR-T for people with advanced HER2-positive solid tumors (like breast, stomach, or colon cancer) whose cancer has not responded to other treatments. The therapy uses your own immune cells engineered to target and kill cancer cells.
This trial tests a new way to take blood from patients with solid tumors or healthy volunteers, grow immune cells in a lab, and then give them back to potentially treat cancer. It may help people whose standard options have run out.
This trial tests a new type of immune cell therapy (CAR-NKT) that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to at least two prior treatments and whose tumors are CD70-positive.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.